IPA Stock Overview
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ImmunoPrecise Antibodies Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.24 |
| 52 Week High | US$4.22 |
| 52 Week Low | US$0.94 |
| Beta | 0.33 |
| 1 Month Change | -11.43% |
| 3 Month Change | -15.07% |
| 1 Year Change | -53.90% |
| 3 Year Change | -87.33% |
| 5 Year Change | -52.49% |
| Change since IPO | -71.42% |
Recent News & Updates
Shareholder Returns
| IPA | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -10.8% | -6.3% | -3.5% |
| 1Y | -53.9% | -6.3% | 20.2% |
Return vs Industry: IPA underperformed the US Life Sciences industry which returned -5.7% over the past year.
Return vs Market: IPA underperformed the US Market which returned 20.9% over the past year.
Price Volatility
| IPA volatility | |
|---|---|
| IPA Average Weekly Movement | 13.5% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IPA's share price has been volatile over the past 3 months.
Volatility Over Time: IPA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 102 | Jennifer Bath | www.ipatherapeutics.com |
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign.
ImmunoPrecise Antibodies Ltd. Fundamentals Summary
| IPA fundamental statistics | |
|---|---|
| Market cap | US$33.95m |
| Earnings (TTM) | -US$10.32m |
| Revenue (TTM) | US$17.14m |
1.9x
P/S Ratio-3.2x
P/E RatioIs IPA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IPA income statement (TTM) | |
|---|---|
| Revenue | CA$23.68m |
| Cost of Revenue | CA$11.39m |
| Gross Profit | CA$12.29m |
| Other Expenses | CA$26.55m |
| Earnings | -CA$14.26m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.54 |
| Gross Margin | 51.88% |
| Net Profit Margin | -60.22% |
| Debt/Equity Ratio | 0% |
How did IPA perform over the long term?
See historical performance and comparison